Function
Locations
Deficiency = MPS II (Hunter syndrome), X-linked.
Heparan sulfate is degraded in the lysosome by an ordered, strictly sequential exolytic cascade that removes one monosaccharide or sulfate group at a time from the non-reducing end of the chain; each enzyme can act only after the preceding one has exposed its substrate, so a deficiency of any single step blocks the whole pathway and causes a mucopolysaccharidosis (MPS) with lysosomal heparan-sulfate storage. Iduronate-2-sulfatase (IDS) first removes the 2-O-sulfate from a terminal iduronate-2-sulfate; alpha-L-iduronidase (IDUA) then hydrolyses the exposed iduronate; sulfamidase (SGSH) removes the N-sulfate from the terminal N-sulfoglucosamine; the lysosomal-membrane transacetylase HGSNAT then N-acetylates the freed glucosamine (using cytosolic acetyl-CoA) so that alpha-N-acetylglucosaminidase (NAGLU) can hydrolyse it; N-acetylglucosamine-6-sulfatase (GNS) removes a 6-O-sulfate; and beta-glucuronidase (GUSB) hydrolyses the terminal glucuronate — regenerating a substrate for IDS/IDUA as the cycle repeats. The three sulfatases (IDS, SGSH, GNS) additionally require the formylglycine catalytic residue generated by SUMF1. Each enzyme defines a distinct disease: MPS II (IDS, Hunter), MPS I (IDUA, Hurler-Scheie), MPS IIIA (SGSH, Sanfilippo A), MPS IIIC (HGSNAT, Sanfilippo C), MPS IIIB (NAGLU, Sanfilippo B), MPS IIID (GNS, Sanfilippo D) and MPS VII (GUSB, Sly).
All recommended fields populated.
✗ none found
No MODULE:heparan_sulfate_lysosomal_degradation deep-research report alongside the module YAML.
✓ every leaf node grounds to a representative protein.
✓ every declared conforms_to bundle matches its template motif.
7 complete review(s) · 0 with deep research · 0 missing review · 7 reviewed but lacking deep research
| Gene | Review | Complete | Deep research |
|---|---|---|---|
| GNS P15586 | ✓ | ✓ | ✗ |
| GUSB P08236 | ✓ | ✓ | ✗ |
| HGSNAT Q68CP4 | ✓ | ✓ | ✗ |
| IDS P22304 | ✓ | ✓ | ✗ |
| IDUA P35475 | ✓ | ✓ | ✗ |
| NAGLU P54802 | ✓ | ✓ | ✗ |
| SGSH P51688 | ✓ | ✓ | ✗ |
Heparan sulfate lysosomal degradation, grounded to the human enzymes IDS (UniProtKB:P22304, GO:0004423, EC 3.1.6.13), IDUA (P35475, GO:0003940, EC 3.2.1.76), SGSH (P51688, GO:0016250, EC 3.10.1.1), HGSNAT (Q68CP4, GO:0015019, EC 2.3.1.78), NAGLU (P54802, GO:0004561, EC 3.2.1.50), GNS (P15586, GO:0008449, EC 3.1.6.14) and GUSB (P08236, GO:0004566, EC 3.2.1.31). GO molecular-function/BP/location terms were taken from the completed human gene reviews and verified against the local go.db; Reactome reaction ids/titles were verified against the local reactome cache. Each step uses a PANTHER family selector with the human enzyme as representative. The pathway is a strictly ordered exolytic cascade acting from the non-reducing end: every step depends on the product of the previous one, which is why a single enzyme deficiency blocks the whole pathway (the biochemical basis of the mucopolysaccharidoses). Six enzymes are soluble lysosomal-lumen hydrolases/sulfatases; HGSNAT is uniquely a polytopic lysosomal-membrane transacetylase that uses cytosolic acetyl-CoA. The three sulfatases (IDS, SGSH, GNS) require the formylglycine catalytic residue generated by the activating enzyme SUMF1 (a separate gene). Upstream, heparan sulfate proteoglycans are delivered to the lysosome; several of these enzymes also degrade dermatan, chondroitin or keratan sulfate (GALNS, ARSB, GLB1 act in those parallel GAG pathways — separate/overlapping modules; ARSB already reviewed). Disorders: MPS II (IDS), MPS I (IDUA), MPS IIIA (SGSH), MPS IIIC (HGSNAT), MPS IIIB (NAGLU), MPS IIID (GNS) and MPS VII (GUSB).
Deficiency = MPS II (Hunter syndrome), X-linked.
Deficiency = MPS I (Hurler, Hurler-Scheie, Scheie).
Deficiency = MPS IIIA (Sanfilippo A).
Deficiency = MPS IIIC (Sanfilippo C).
Deficiency = MPS IIIB (Sanfilippo B).
Deficiency = MPS IIID (Sanfilippo D).
Deficiency = MPS VII (Sly syndrome).